CN1895666A - Cow mastitis concatenate inactivated vaccine - Google Patents
Cow mastitis concatenate inactivated vaccine Download PDFInfo
- Publication number
- CN1895666A CN1895666A CN 200510012160 CN200510012160A CN1895666A CN 1895666 A CN1895666 A CN 1895666A CN 200510012160 CN200510012160 CN 200510012160 CN 200510012160 A CN200510012160 A CN 200510012160A CN 1895666 A CN1895666 A CN 1895666A
- Authority
- CN
- China
- Prior art keywords
- streptococcus
- concatenate
- inactivated
- cow
- inactivated vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004396 mastitis Diseases 0.000 title claims abstract description 28
- 229940031551 inactivated vaccine Drugs 0.000 title claims description 21
- 239000007788 liquid Substances 0.000 claims abstract description 29
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 17
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 21
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 17
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims description 17
- 229940030998 streptococcus agalactiae Drugs 0.000 claims description 17
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims description 17
- 241000194054 Streptococcus uberis Species 0.000 claims description 16
- 229940115922 streptococcus uberis Drugs 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 239000004411 aluminium Substances 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 8
- 230000009849 deactivation Effects 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 241000295644 Staphylococcaceae Species 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 229940023064 escherichia coli Drugs 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940033663 thimerosal Drugs 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 19
- 235000013336 milk Nutrition 0.000 abstract description 11
- 239000008267 milk Substances 0.000 abstract description 11
- 210000004080 milk Anatomy 0.000 abstract description 11
- 241000194017 Streptococcus Species 0.000 abstract description 4
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000003405 preventing effect Effects 0.000 abstract description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 35
- 238000011081 inoculation Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000006161 blood agar Substances 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 241000241413 Propolis Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940069949 propolis Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100038103 Protein-glutamine gamma-glutamyltransferase 4 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000767 hemotoxin Toxicity 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000009 lactational effect Effects 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- -1 plasma-coagulase Proteins 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An deactivated multi-bacterium vaccine for preventing the mastitis of milk cow is composed of Staphylococcus aureus, agalactic streptococcus, milk-stopping streptococcus, breast streptococcus, colibacillus and aluminum hydroxide gel. Its preparing process includes such steps as choosing the pathogenic bacterial strain of said mastitis, preparing seed liquid and reproduction liquid, purity checking, deactivating, preparing vaccine, and discriminating.
Description
Technical field
What the present invention relates to is a kind of veterinary biologics and preparation method thereof, or rather, relates to a kind of concatenate inactivated vaccine that prevents mammitis of cow and preparation method thereof.
Background technology
Mammitis of cow (Bovine Mastitis) is the inflammation of cow mammary gland tissue, is mainly due to the microorganism of mammary gland tissue pathogenic infection, is commonly encountered diseases, the frequently-occurring disease of milch cow.Can be divided into recessive type and clinic mastitis according to clinical manifestation.The pathogenic bacterium that cause mammitis of cow are about kind more than 150, based on staphylococcus aureus, streptococcus and escherichia coli, account for more than 90% of whole mammitis of cow case.Its principal character is that milk generation physicochemical property and bacteriology change, and mammary gland tissue generation pathology change.The most important variation of milk is that color changes, and grumeleuse and a large amount of cell are arranged in the milk.When mastitis took place, though enlargement and pain occur at many case mammary gland, most of recessive mammitis of cow cases were difficult to note abnormalities with the hands palpation time, and macroscopy also is difficult to observe pathological change.
At present to the control of mammitis of cow, still be controlled to be the master with antibiotic therapy and environmental health, but antibiotic therapy is usually because chemical sproof generation and unsatisfactory curative effect causes serious Ruzhong antibiotic remains, harm humans is healthy.At this problem, begun one's study in the last few years both at home and abroad and use the vaccine immunization method to prevent and control primary disease, and received certain effect, from staphylococcus aureus, isolate three kinds of bacterial strains as people such as Ze ' ev Trainin, make the sterilization vaccine with control cattle and sheep breast infection of staphylococcus aureus (patent application WO99/33954) with it, people such as Luo Jinyin (" Chinese veterinary's science and technology ", 2003,33 (4): 61-63) with staphylococcus aureus, streptococcus agalactiae and streptococcus dysgalactiae mix by a certain percentage and are aided with adjuvant and have made the aluminium glue vaccine, oil emulsion vaccine, the propolis vaccine, liposome bacterin and liposome propolis vaccine, propolis vaccine in clinical milk cattle immunity inoculation experiment, oil emulsion vaccine and aluminium glue vaccine all show certain effect, but the overall immune level is high not enough.
Summary of the invention
Purpose of the present invention aim to provide a kind of cost low, safely, can be used in concatenate inactivated vaccine of prevention milk cow recessive and clinic mastitis and preparation method thereof.
Cow mastitis concatenate inactivated vaccine of the present invention, comprise that (before mixing, gold-coloured staphylococci, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary concentration separately are 6 * 10 with the ratio of equivalent by staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary inactivated bacterial liquid
10CFU/ml.) mix the bacterium liquid that obtains, also comprise 20% gel aluminum hydroxide through sterilization, wherein the ratio by volume of mixed bacteria liquid and 20% gel aluminum hydroxide is 4: 1.
The preparation method of concatenate inactivated vaccine of the present invention is as follows: (1) selects for use clinical type mammitis of cow pathogenic strain as the seedling bacterial strain; (2) seed liquor and the germ-increasing liquid of preparation vaccine production usefulness; (3) pure inspection and deactivation; (4) preparation aluminium glue concatenate inactivated vaccine; (5) steriling test, safety examination and efficacy test.
Concrete steps are as follows:
(1) select for use clinical type mammitis of cow pathogenic strain as the seedling bacterial strain
With staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis streak inoculation in containing 5% sheep blood agar culture medium, the escherichia coli streak inoculation is in Yihong methylene blue and Mai Kangkai culture medium, cultivate 24h for 37 ℃, observe the colony growth situation, biochemical characteristic carries out according to a conventional method.Each strain morphology and main biochemical characteristic should meet the feature of bacterial strain separately, have following feature as the pathogenic detection of staphylococcus aureus: can produce pod membrane and hemotoxin, mannose ferment, catalase, plasma-coagulase, fibrinoligase, heat-resisting Dnase test all positive.
(2) seed liquor and the germ-increasing liquid of preparation vaccine production usefulness
Strain is inoculated in 10% sheep blood agar culture-medium respectively, cultivate 24h for 37 ℃, pure culture through the biological characteristics assay approval, staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis are inoculated in an amount of BHI fluid medium respectively, escherichia coli are inoculated in the TSB fluid medium, cultivate 20～24h 37 ℃ of concussions, place 2～8 ℃ of preservations, as seed liquor.Seed liquor is inoculated in respectively in BHI and the TSB fluid medium by 1～2% amount, cultivates 20～24h, shaken cultivation or aerobic culture continuously at 37 ℃.It is standby that bacteria suspension is put 2～8 ℃ of preservations.
(3) pure inspection and deactivation
After bacterium liquid is cultivated and is finished, sampling is done pure inspection and is calculated the bacterium number respectively, add final concentration in the qualified bacterium liquid respectively and be 0.4% formalin (v/v), 37 ℃ of shaken cultivation 24h, after the deactivation thoroughly, under 4 ℃ of conditions, the centrifugal 20min of 7000rpm/min, the PBS that uses normal saline or pH7.2 washs 3 times, gets the inactivated bacteria suspension.Wherein gold-coloured staphylococci, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary concentration separately are 6 * 10
10CFU/mL.Each inactivated bacterial liquid adds 0.01% thimerosal respectively, and mixing is placed on 2～8 ℃ of preservations.
(4) preparation aluminium glue concatenate inactivated vaccine
With 5 kinds of inactivated bacterial liquid equal-volumes of gained mixing, per 4 parts of bacterium liquid add 1 part of 20% aluminium hydroxide gel through sterilization, mixing, and the aluminium glue concatenate inactivated vaccine is made in packing; Carry out steriling test, safety examination and efficacy test after vaccine fully vibrates, qualified after, put dark cold place and preserve.
(5) steriling test, safety examination and efficacy test
The product that adopts method of the present invention to produce can be used for preventing milk cow recessive and clinic mastitis.
Product advantage applies of the present invention exists:
(1) since this seedling bacterium liquid through the thorough deactivation of formaldehyde, so safety, exhausted not have the poison of loosing dangerous.
(2) prepare concatenate inactivated vaccine, its good immune effect, high specificity as the strong a plurality of bacterial strains of immunogenicity.
(3) production technology advanced person, stable performance, production cost is low, and the added value of product height is fit to batch production production, and market application foreground is wide.
The specific embodiment
Can further be expressly understood the present invention by specific embodiments of the invention given below and safety and immuning effect test, but following embodiment not a limitation of the invention.
Embodiment 1
Depletion Staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis streak inoculation are in containing 5% sheep blood agar culture medium, the escherichia coli streak inoculation is in Yihong methylene blue and Mai Kangkai culture medium, cultivate 24h for 37 ℃, observe the colony growth situation and identify its characteristic with the routine biochemistry method.
Isolated strain is inoculated in 10% sheep blood agar culture-medium respectively, cultivate 24h for 37 ℃, pure culture through the biological characteristics assay approval, staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis are inoculated in an amount of BHI fluid medium respectively, escherichia coli are inoculated in the TSB fluid medium, cultivate 24h 37 ℃ of concussions, place 4 ℃ of preservations, as seed liquor.Seed liquor is inoculated in respectively in BHI and the TSB fluid medium by 1.5% amount, cultivates 24h, shaken cultivation or aerobic culture continuously at 37 ℃.It is standby that the gained bacteria suspension is put 4 ℃ of preservations.
After bacterium liquid was cultivated and finished, pure inspection was done in sampling respectively, calculates the bacterium number simultaneously, by centrifugal, concentrated, gold-coloured staphylococci, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary concentration all was adjusted into 6 * 10
10CFU/mL.Add final concentration in each bacterium liquid respectively and be 0.4% formalin (v/v), 37 ℃ of shaken cultivation 24h, after the deactivation thoroughly, under 4 ℃ of conditions, the centrifugal 20min of 7000rpm/min, the PBS washing 3 times of using normal saline or pH7.2, the inactivated bacteria suspension.Each inactivated bacterial liquid adds 0.01% thimerosal respectively, and mixing is placed on 4 ℃ of preservations.
With 5 kinds of inactivated bacterial liquid equal-volumes of gained mixing, per 4 parts of bacterium liquid add 1 part of 20% aluminium hydroxide gel through sterilization, mixing, and the aluminium glue concatenate inactivated vaccine is made in packing; Carry out steriling test, safety examination and efficacy test after vaccine fully vibrates, qualified after, put dark cold place and preserve.
Embodiment 2
(1) safety testing
Select 10 abdominal cavity inoculations of 21-25 age in days standard white mice 1mL vaccine, 5 of healthy rabbits, back subcutaneous vaccination 1mL vaccine is observed 14d.The result is all normal, the no abnormality seen symptom.
Select each 4 of healthy growing cattle, normal lactation cattle and conceived cows, inoculate embodiment 1 gained concatenate inactivated vaccine respectively, branch injection 10mL observes 7d under every Corii Bovis seu Bubali, checks the reaction of inoculating local and whole body.The result has only 1 growing cattle injection site swelling, recovers normal about 1 week; Other inoculation cattle all do not have obvious part and general reaction.Spirit, body temperature, appetite, breathing and pulse are normal, and lactogenic cow milk yield is normal, and conceived cow fetus is normal, do not have the miscarriage phenomenon.
(2) immuning effect test
Get 50 of health standards white mice, be divided into two groups, 25 every group.Every subcutaneous injection embodiment of one group of white mice 1 gained concatenate inactivated vaccine 0.5mL, another group subcutaneous injection normal saline 0.5mL.Behind the 15d, use (10 of lethal dose respectively for two groups
7CFU/mL) staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and escherichia coli liquid culture counteracting toxic substances, every group of each bacterial strain inoculated 5 white mice in the abdominal cavity respectively, and every inoculation 1mL observes a week.Immune group of streptococcus agalactiae and streptococcus uberis and matched group there is no death as a result, because these two kinds of antibacterials do not have pathogenic to white mice; Except that the mice dying of 1 injection streptococcus dysgalactiae, all the other are all strong alive in other test immune group, and matched group is all dead.
(3) clinical immunity test
Under same feeding and management condition, test has selected a milch cow sub-district not have the milk cow in lactation period 100 of mastitis clinical symptoms at random, Application Example 1 gained vaccine 21d at interval carries out immunity inoculation twice, and each cervical region subcutaneous vaccination 5mL establishes 100 of matched groups simultaneously.Also select a milch cow sub-district not have dry milk phase 30 of the milch cows of mastitis clinical symptoms in addition, established 30 of matched groups simultaneously.When dry milk, antenatal 30d and puerperal 48h carry out 3 immunity, each cervical region subcutaneous vaccination 5mL.2 weeks were observed in the immunity back, and the spirit of milch cow, appetite, body temperature, injection site and lactation amount are all normal.Whole lactational clinical onset situation is observed after immunity, and two milch cow sub-district immunity cows are respectively 60% and 81% to the protective rate of clinical type mammitis of cow.
Evidence: cow mastitis concatenate inactivated vaccine is to growing cattle, normal lactation cattle and conceived cow all safety, little, the non-evident effect of toxicity; This vaccine immunization white mice 15d produces strong immunity, and protective rate reaches more than 80%; Clinical practice shows that clinic mastitis is had the good preventing effect, and especially dry milk cattle immune effect is better, and protective rate reaches 81%, and immune duration is the longest to reach 10 months.
Claims (5)
1, a kind of cow mastitis concatenate inactivated vaccine, form by the mixing inactivated bacterial liquid of clinical type mammitis of cow pathogenic bacterium with through 20% gel aluminum hydroxide of sterilization, wherein clinical type mammitis of cow pathogenic bacterium comprise staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis.
2, concatenate inactivated vaccine according to claim 1, the mixing inactivated bacterial liquid of wherein clinical type mammitis of cow pathogenic bacterium is formulated with isopyknic ratio by staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis, colibacillary inactivated bacterial liquid.
3, concatenate inactivated vaccine as claimed in claim 1 or 2, it mixes inactivated bacterial liquid staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary concentration separately before mixing and is 6 * 10
10CFU/ml.
4, concatenate inactivated vaccine as claimed in claim 1 or 2, the ratio by volume that it is characterized in that mixed bacteria liquid and 20% gel aluminum hydroxide is 4: 1.
5, the preparation method of concatenate inactivated vaccine as claimed in claim 1 or 2, its step is as follows:
(1) choose clinical type mammitis of cow pathogenic strain staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and escherichia coli, biochemical characteristic detects qualified back as the seedling bacterial strain.
(2) staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis are inoculated in the BHI fluid medium respectively, and escherichia coli are inoculated in the TSB fluid medium, cultivate 24h for 37 ℃, as seed liquor.Seed liquor is inoculated in respectively in BHI and the TSB fluid medium by 1～2% amount, 37 ℃ of vibrations or continuously aerobic culture 20～24h prepare germ-increasing liquid.
(3) pure inspection is done in sampling to step (2) gained bacterium liquid, calculates the bacterium number simultaneously.It is 0.4% formalin (v/v) that gained bacterium liquid adds ultimate density respectively, and 37 ℃ of shaken cultivation 24h deactivation is after the deactivation thoroughly, under 4 ℃ of conditions, the centrifugal 20min of 7000rpm/min removes supernatant, the PBS that precipitate is used normal saline or pH7.2 washs 3 times, gets the inactivated bacteria suspension.Wherein gold-coloured staphylococci, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and colibacillary concentration separately are 6 * 10
10CFU/mL.Add 0.01% thimerosal in each inactivated bacterial liquid respectively, mixing is placed on 2～8 ℃ of preservations.
(4) with each inactivated bacterial liquid equal-volume mixing of gained, per 4 parts of mixed bacteria liquids add 1 part of 20% gel aluminum hydroxide through sterilization and make the aluminium glue concatenate inactivated vaccine.
(5) gained aluminium glue concatenate inactivated vaccine is carried out steriling test, safety examination and efficacy test.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100121609A CN100536917C (en) | 2005-07-13 | 2005-07-13 | Cow mastitis concatenate inactivated vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100121609A CN100536917C (en) | 2005-07-13 | 2005-07-13 | Cow mastitis concatenate inactivated vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895666A true CN1895666A (en) | 2007-01-17 |
| CN100536917C CN100536917C (en) | 2009-09-09 |
Family
ID=37608409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100121609A Expired - Fee Related CN100536917C (en) | 2005-07-13 | 2005-07-13 | Cow mastitis concatenate inactivated vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100536917C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979089A (en) * | 2010-11-17 | 2011-02-23 | 赤峰博恩药业有限公司 | Bovine staphylococcus aureus mastitis inactivated vaccine and preparation method thereof |
| CN101991847A (en) * | 2010-11-16 | 2011-03-30 | 赤峰博恩药业有限公司 | Triple inactivated vaccine against dairy cattle mastitis and preparation method thereof |
| CN102205117A (en) * | 2011-05-19 | 2011-10-05 | 新疆维吾尔自治区畜牧科学院兽医研究所 | Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof |
| CN102294026A (en) * | 2010-11-17 | 2011-12-28 | 赤峰博恩药业有限公司 | Milk cow streptococcal mastitis inactivated vaccine and preparation method thereof |
| CN101693109B (en) * | 2009-10-23 | 2012-02-08 | 天津市畜牧兽医研究所 | Yeast glucan synergistic inactivated vaccine for preventing staphylococcus aureus mastitis in dairy cows |
| CN103800899A (en) * | 2014-01-27 | 2014-05-21 | 内蒙古华希生物科技有限公司 | Milk cattle mastitis vaccine |
| CN103800901A (en) * | 2014-01-27 | 2014-05-21 | 内蒙古华希生物科技有限公司 | Streptococcus and dairy cow mastitis vaccine obtained by inactivating streptococcus |
| CN106496325A (en) * | 2016-09-27 | 2017-03-15 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of microcapsule is coated the preparation method and application of anti-main pathogen of bovine mastitis yolk antibody IgY |
| CN114015622A (en) * | 2021-12-14 | 2022-02-08 | 塔里木大学 | Streptococcus agalactiae culture medium and preparation method thereof |
| CN114042153A (en) * | 2021-09-30 | 2022-02-15 | 内蒙古华希生物科技有限公司 | Multiple inactivated vaccine for dairy cow mastitis and preparation method and application thereof |
-
2005
- 2005-07-13 CN CNB2005100121609A patent/CN100536917C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693109B (en) * | 2009-10-23 | 2012-02-08 | 天津市畜牧兽医研究所 | Yeast glucan synergistic inactivated vaccine for preventing staphylococcus aureus mastitis in dairy cows |
| CN101991847A (en) * | 2010-11-16 | 2011-03-30 | 赤峰博恩药业有限公司 | Triple inactivated vaccine against dairy cattle mastitis and preparation method thereof |
| CN101979089A (en) * | 2010-11-17 | 2011-02-23 | 赤峰博恩药业有限公司 | Bovine staphylococcus aureus mastitis inactivated vaccine and preparation method thereof |
| CN102294026A (en) * | 2010-11-17 | 2011-12-28 | 赤峰博恩药业有限公司 | Milk cow streptococcal mastitis inactivated vaccine and preparation method thereof |
| CN102205117A (en) * | 2011-05-19 | 2011-10-05 | 新疆维吾尔自治区畜牧科学院兽医研究所 | Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof |
| CN103800899A (en) * | 2014-01-27 | 2014-05-21 | 内蒙古华希生物科技有限公司 | Milk cattle mastitis vaccine |
| CN103800901A (en) * | 2014-01-27 | 2014-05-21 | 内蒙古华希生物科技有限公司 | Streptococcus and dairy cow mastitis vaccine obtained by inactivating streptococcus |
| CN103800901B (en) * | 2014-01-27 | 2015-12-09 | 内蒙古华希生物科技有限公司 | Streptococcus and the mammitis of cow vaccine that its deactivation is obtained |
| CN106496325A (en) * | 2016-09-27 | 2017-03-15 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of microcapsule is coated the preparation method and application of anti-main pathogen of bovine mastitis yolk antibody IgY |
| CN114042153A (en) * | 2021-09-30 | 2022-02-15 | 内蒙古华希生物科技有限公司 | Multiple inactivated vaccine for dairy cow mastitis and preparation method and application thereof |
| CN114042153B (en) * | 2021-09-30 | 2023-10-13 | 内蒙古华希生物科技有限公司 | Milk cow mastitis multi-linked inactivated vaccine and preparation method and application thereof |
| CN114015622A (en) * | 2021-12-14 | 2022-02-08 | 塔里木大学 | Streptococcus agalactiae culture medium and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100536917C (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100536917C (en) | Cow mastitis concatenate inactivated vaccine | |
| Meleney | Bacterial synergism in disease processes: with a confirmation of the synergistic bacterial etiology of a certain type of progressive gangrene of the abdorminal wall | |
| CN1057563C (en) | Bacterial stain of bacillus subtilis and application thereof | |
| CN113082060B (en) | Preparation and application of phage cocktail preparation for treating dairy cow mastitis | |
| Havas et al. | Mixed Bacterial Toxins in the Treatment of Tumors: I. Methods of Preparation and Effects on Normal and Sarcoma 37-bearing Mice | |
| CN102626516A (en) | Pseudomonas aeruginosa and propolis inactivated vaccine for minks and preparation process | |
| CN114129547B (en) | Application of carvacrol in improving sensitivity of methicillin-resistant staphylococcus aureus to beta-lactam antibiotics | |
| CN110812473A (en) | Triple inactivated vaccine for haemophilus parasuis disease, streptococcus suis disease and pasteurella multocida disease and preparation method thereof | |
| TOMPSETT et al. | Enterococcal endocarditis: Lack of correlation between therapeutic results and antibiotic sensitivity tests | |
| CN115350197B (en) | Application of alisol A-24-acetate in improving sensitivity of MRSA to beta-lactam antibiotics | |
| JPH07108857B2 (en) | Bacterial preparations for the prevention and treatment of inflammatory processes and allergic diseases | |
| US20020114794A1 (en) | Staphylococcus aureus culture and preparation thereof | |
| CN1177637A (en) | Preparation of living bacillus subtilis and preparation method thereof | |
| CN108273051B (en) | The rapidly and efficiently preparation method of pig A type C.perfringens inactivated vaccine | |
| CN113559256B (en) | Nocardia immunopotentiator and application thereof in preparation of pig vaccine | |
| RU2367454C1 (en) | Intime hygiene product "femivit" | |
| Knothe | The effect of trimethoprim-sulphonamide, trimethoprim and sulphonamide on the occurrence of resistant Enterobacteriaceae in human intestinal flora | |
| Furness et al. | Isolation of diphtheroids from non-gonococcal urethritis. | |
| Holman | CHAPTER VIII BACTERIAL ASSOCIATIONS | |
| CN101693109B (en) | Yeast glucan synergistic inactivated vaccine for preventing staphylococcus aureus mastitis in dairy cows | |
| CN102908610B (en) | Propolis combination used for livestock and preparation method of same | |
| US3836648A (en) | Treatment of canine distemper with a microbial product derived from the bacterium achromobacter stenohalis | |
| CN109053881A (en) | A kind of special yolk polyclonal antibody and its application | |
| CN100352915C (en) | Bacillus subtilis, composite preparation, and method for preparing the composite preparation | |
| RU2158302C2 (en) | Nutrient medium for bifidobacterium and lactobacterium culturing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG BAYI LAND RECLAMATION UNIV. Free format text: FORMER OWNER: CUI YUDONG Effective date: 20110114 Free format text: FORMER OWNER: ZHU ZHANBO PU FANZE |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 163319 AGRICULTURAL UNIVERSITY RESIDENTIAL AREA, BAYI, HIGH-TECH. DEVELOPMENT AREA, DAQING CITY, HEILONGJIANG PROVINCE TO: 163319 HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY, DAQING CITY, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110114 Address after: 163319 Heilongjiang Bayi Agricultural University, Heilongjiang, Daqing Patentee after: Heilongjiang Bayi Agricultural University Address before: 163319 Daqing Heilongjiang hi tech Development Zone Bayi Agricultural University residential area Co-patentee before: Zhu Zhanbo Patentee before: Cui Yudong Co-patentee before: Pu Fanze |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090909 Termination date: 20130713 |